EUVIMEDEUVIMED entdecken
Open Access

Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease

Elizabeth A Spencer iD, Suzannah Bergstein, Michael Dolinger iD, Nanci Pittman, Amelia Kellar, David Dunkin iD, Marla C Dubinsky

Inflammatory Bowel Diseases · 2024

DOI: 10.1093/ibd/izad300 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Elizabeth A Spencer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics Mount Sinai, Icahn School of Medicine, 17 E. 102nd Street, Fifth Floor…. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Colitis, Ulcerative. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Upadacitinib (UPA) is a novel selective JAK inhibitor approved for adults with ulcerative colitis (UC) and with positive phase 3 data for Crohn’s disease (CD). Pediatric off-label use is common due to delays in pediatric approvals; real-world data on UPA are needed to understand the safety and effectiveness in pediatric IBD.

Methods

This is a single-center retrospective case series study of adolescents (12-17 years) with inflammatory bowel disease IBD on UPA. The primary outcome was postinduction steroid-free clinical remission (SF-CR) defined as Pediatric UC Activity Index (PUCAI) or Pediatric CD Activity Index (PCDAI) ≤10. Secondary outcomes include postinduction clinical response (decrease ≥12.5 in PUCAI/PCDAI), postinduction C-reactive protein (CRP) normalization, 6-month SF-CR, and intestinal ultrasound response and remission. Adverse events were recorded through last follow-up.

Results

Twenty patients (9 CD, 10 UC, 1 IBD-U; 55% female; median age 15 years, 90% ≥2 biologics) were treated with UPA for ≥12 weeks (median 51 [43-63] weeks). Upadacitinib was used as monotherapy in 55% and as combination with ustekinumab and vedolizumab in 35% and 10%, respectively. Week 12 SF-CR was achieved in 75% (15/20) and 80% (16/20) with CRP normalization. About 3/4 (14/19) achieved SF-CR at 6 months. Adverse event occurred in 2 patients (10%): Cytomegalovirus colitis requiring hospitalization and hyperlipidemia requiring no treatment. In the 75% with ultrasound monitoring, response and remission were achieved in 77% and 60%, respectively.

Conclusion

While awaiting pediatric registration trials, our data suggest that UPA is effective in inducing and maintaining SF-CR in adolescents with highly-refractory IBD with an acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heterocyclic Compounds, 3-RingColitis, UlcerativeHumansAdolescentFemaleMaleRetrospective StudiesChildRemission InductionJanus Kinase InhibitorsCrohn DiseaseTreatment OutcomeInflammatory Bowel Diseases

Stichwörter der Autor:innen

Crohn’s diseaseadolescentinflammatory bowel diseasepediatriculcerative colitisupadacitinib

Substanzen

upadacitinibHeterocyclic Compounds, 3-RingJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Pediatric Gastroenterology and Nutrition, Department of Pediatrics Mount Sinai, Icahn School of Medicine, 17 E. 102nd Street, Fifth Floor, New York, NY, 10029, USA.

ORCID-Profile: Elizabeth A Spencer, Michael Dolinger, David Dunkin

Förderung

  • NIDDK NIH HHS
  • NIH

Zitieren

APA

Spencer, E. A., Bergstein, S., Dolinger, M., Pittman, N., Kellar, A., Dunkin, D., & Dubinsky, M. C. (2024). Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad300

Vancouver

Spencer EA, Bergstein S, Dolinger M, Pittman N, Kellar A, Dunkin D, et al. Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad300

BibTeX
@article{Spencer2024,
  author = {Spencer, Elizabeth A and Bergstein, Suzannah and Dolinger, Michael and Pittman, Nanci and Kellar, Amelia and Dunkin, David and Dubinsky, Marla C},
  title = {Single-center Experience With Upadacitinib for Adolescents With Refractory Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  doi = {10.1093/ibd/izad300}
}
Kostenlos starten →